業績

業績（論文）

[公開日] 2018年8月9日　[最終更新日] 2025年6月24日

代表的な論文（2025年6月更新）

2025年

  • Kondo S, Kitano S, Sato J, Katsuya Y, Kogawa T, Mizugaki H, Miyamoto I, Iwasawa S, Imaizumi T, Tomita H, Murakami C, Miyake T, Yamamoto N. :An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks. :Invest New Drugs, 2025
  • Seto T, Nakane S, Ji L, Ueda Y, Sugano H, Takei N, Kobayashi M, Murayama A, Yamamoto N.:
    Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance: Lung Cancer.203:108478., 2025
  • Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators.: Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer:N Engl J Med., 2025
  • Fukuda A, Mizuno T, Yoshida T, Sunami K, Kubo T, Koyama T, Yonemori K, Okusaka T, Kato K, Ohe Y, Yatabe Y, Yamamoto N.: Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing: Jpn J Clin Oncol, 2025
  • Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schröter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N.: HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study: J Clin Oncol. 43(11):1337-1347., 2025
  • Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y.: Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma: Lung Cancer.:202:108494., 2025
  • Uehara Y, Koyama T, Katsuya Y, Sato J, Sudo K, Kondo S, Yoshida T, Shoji H, Shimoi T, Okada M, Yonemori K, Yamamoto N: Impact of travel costs on disparities in precision oncology clinical trials. ESMO Real World Data and Digital Oncology 7, 2025
  • Kitadai R, Okuma Y, Shibata T, Kohno T, Koyama T: Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository. Eur J Cancer 220:115380, 2025
  • Katsuya Y, Ikeda M, Koyama T, Sato J, Okada M, Matsubara N, Kondoh C, Mukohara T, Watanabe K, Kotani D, Ogawa Y, Taoka S, Yamamoto N, A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors. Cancer Sci. 2025 116(1):..
  • Nishimura R, Sudo K, Kitadai R, Kawachi A, Ito M, Hoshino M, Kita S, Saito A, Kojima Y, Maejima A, Noguchi E, Okuma HS, Koyama T, Shimoi T, Yonemori K: Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test. Oncology:1-10, 2025
  • Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM: Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. J Clin Oncol:Jco2401534, 2025
  • Hamamoto R, Komatsu M, Yamada M, Kobayashi K, Takahashi M, Miyake M, Jinnai S, Koyama T, Kouno N, Machino H, Takahashi S, Asada K, Ueda N, Kaneko S: Current status and future direction of cancer research using artificial intelligence for clinical application. Cancer Sci 116:297-307, 2025
  • Fujii E, Kato MK, Ono H, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H: TP53 Mutations and PD-L1 Amplification in Vulvar Adenocarcinoma of the Intestinal Type: Insights From Whole Exome Sequencing of 2 Cases. Int J Gynecol Pathol, 2025
  • Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, Waizenegger IC, Gerlach D, Augsten M, Spreitzer F, Shirai Y, Ikegami M, Tilandyová S, Scharn D, Pearson MA, Popow J, Obenauf AC, Yamamoto N, Kondo S, Opdam FL, Bruining A, Kohsaka S, Kraut N, Heymach JV, Solca F, Neumüller RA.: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers,:Cancer Discov.:15(1):119-138., 2025
  • Masuda K, Yoshida T, Motoi N, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Hoshino T, Yatabe Y, Ohe Y.: Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes: Thorac Cancer. 16(1):e15529., 2025

    • 2024年

    • Murata S, Horinouchi H, Morishita M, Kaku S, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Kashihara T, Okuma K, Kusumoto M, Ohe Y.: Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy: Clin Lung Cancer. 25(7):e369-e378.e3., 2024
    • Baba S, Kawasaki T, Hirano S, Nakamura T, Asano T, Okazaki R, Yoshida K, Kawase T, Kurahara H, Oi H, Yokoyama M, Kita J, Imura J, Kinoshita K, Kondo S, Okada M, Satake T, Igawa YS, Yoshida T, Yamaguchi H, Ando Y, Mizunuma M, Ichikawa Y, Hida K, Nishihara H, Kato Y.: A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study:　EClinicalMedicine. 78:102936., 2024
    • Igawa Y, Yoshida T, Makihara R, Torasawa M, Tateishi A, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.: Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification: Lung Cancer. 196:107954., 2024
    • Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, Kondo S, Yonemori K, Kawasaki A, Satake K, Shibata S, Shimizu T.: Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors: Cancer Chemother Pharmacol. 94(3):491., 2024
    • Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, Kondo S, Yonemori K, Kawasaki A, Satake K, Shibata S, Shimizu T: Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 94:109-115, 2024
    • Sato J, Sadachi R, Koyama T, Katsuya Y, Okada M, Yamamoto N: Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan. Front Med (Lausanne) 11:1390083, 2024
    • Koyama T, Yonemori K, Shimizu T, Sato J, Kondo S, Sudo K, Yoshida T, Katsuya Y, Imaizumi T, Enomoto M, Seki R, Yamamoto N: Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer Res Commun 4:2349-2358, 2024
    • Sato J, Sadachi R, Koyama T, Katsuya Y, Okada M, Yamamoto N, Regional diversity in drug-induced lung diseases among the
      USA, European Union, and Japan. Front Med (Lausanne). 2024 11:1390083..
    • Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, Kondo S, Yonemori K, Kawasaki A, Satake K, Shibata S, Shimizu T, Correction to: Phase I study of the anti TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol. 2024 94(3):491..
    • Yamamoto N, Kuboki Y, Harano K, Koyama T, Kondo S, Hagiwara A, Suzuki N, Fujikawa E, Toyoizumi K, Mukai M, Doi T: A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. Invest New Drugs 42:376-385, 2024
    • Yamamoto N, Kitano S, Koyama T, Ikeda M, Mizugaki H, Narikiyo T, Yamaguchi Y, Ishida T, Takubo R, Ogami C, Sekiya M, Nakagawa Y, Kuboki Y: Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers. J Immunother Cancer 12, 2024
    • Takamizawa S, Koyama T, Sunami K, Sudo K, Hirata M, Kubo T, Tao K, Cho H, Narita Y, Kato K, Yamazaki N, Ohe Y, Okusaka T, Matsui Y, Ogawa C, Yonemori K, Yamamoto N: Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer Sci 115:2023-2035, 2024
    • Niho S, Sato J, Satouchi M, Itoh S, Okuma Y, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Machida R, Ohe Y, Tamai T, Ikezawa H, Yamamoto N, Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 2024 191:107557..
    • Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, Yonemori K, Yoh K, Gu Y, Mita T, Chen X, Ueda E, Yamamoto N, Doi T, Shimizu T: PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer Med 13:e6980, 2024
    • Shirai Y, Ueno T, Kojima S, Ikeuchi H, Kitada R, Koyama T, Takahashi F, Takahashi K, Ichimura K, Yoshida A, Sugino H, Mano H, Narita Y, Takahashi M, Kohsaka S: The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma. J Neurooncol 167:75-88, 2024

      • 2023年

      • Uehara Y, Koyama T, Katsuya Y, Sato J, Sudo K, Kondo S, Yoshida T, Shoji H, Shimoi T, Yonemori K, Yamamoto N, Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital. JAMA Netw Open. 2023 6(9):e2333188..
      • Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, Sato J, Koyama T, Iwasa S, Sudo K, Kondo S, Yonemori K, Shitara K, Shiono S, Matsuoka D, Yasuda K, Otake Y, Suzuki T, Takase T, Takashima S, Yamaguchi K, Semba T, Yamamoto N, Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer Res Commun. 2023 3(7):1189-1199..
      • Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto, First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4. alone and with nivolumab in solid tumors. Cancer science. 2023 114(1):211-220..
      • Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N: First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors. Cancer Sci 114:211-220, 2023
      • Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S: High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer. Mol Cancer Ther 22:227-239, 2023
      • Asami Y, Kobayashi Kato M, Hiranuma K, Matsuda M, Shimada Y, Ishikawa M, Koyama T, Komatsu M, Hamamoto R, Nagashima M, Terao Y, Itakura A, Kohno T, Sekizawa A, Matsumoto K, Kato T, Shiraishi K, Yoshida H: Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer. Br J Cancer, 2023
      • Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma. Front Oncol. 2023 Jan 9;12:966527.
      • Takamizawa S, Katsuya Y, Chen YN, Mizuno T, Koyama T, Sudo K, Yoshida T, Kondo S, Iwasa S, Yonemori K, Shimizu T, Yamamoto N, Suzuki S. Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials. Invest New Drugs. 2023 Feb;41(1):173-181.
      • Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Sci. 2023 Jan;114(1):211-220.

        • 2022年

        • Rumi Nishimura, Hiroto Ishiki, Jun Sato, Eriko Satomi. Dexamethasone for cancer-related dyspnoea. The Lancet. Oncology. 2022:23(12):e525..
        • Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Keiichi Kikuchi, Kenichiro Akaike, Shiho Takeda, Masayuki Takeda. Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. Investigational new drugs. 2022:41(1):1-12..
        • Shinobu Uzu, Jun Sato, Rika Wakao, Takahiro Nonaka. Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan. BMC health services research. 2022:22(1):1292-1292..
        • Takafumi Koyama, Toshio Shimizu, Jun Sato, Yuki Katsuya, Satoru Iwasa, Shunsuke Kondo, Tatsuya Yoshida, Kazuki Sudo, Makoto Nishino, Yuichi Takiguchi, Kan Yonemori, Noboru Yamamoto. Practical consideration for successful sequential tumor biopsies in first-in-human trials. Investigational new drugs. 2022:40(4):841-849..
        • Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research. 2022:8(9):1783-1791..
        • Takaaki Mizuno, Yuki Katsuya, Jun Sato, Takafumi Koyama, Toshio Shimizu, Noboru Yamamoto, Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU. and China. Frontiers in oncology. 2022 925938:-925938..
        • Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin CC, Suarez C, de Vos F, Steeghs N, Cassier PA, Tai D, Kiladjian JJ, Yamamoto N, Mous R, Esteve J, Minami H, Ferretti S, Guerreiro N, Meille C, Radhakrishnan R, Pereira B, Mariconti L, Halilovic E, Fabre C, Carpio C: Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clin Cancer Res 28:870-881, 2022
        • Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N: Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clin Cancer Res 28:1783-1791, 2022
        • Ida H, Koyama T, Mizuno T, Sunami K, Kubo T, Sudo K, Tao K, Hirata M, Yonemori K, Kato K, Okusaka T, Ohe Y, Matsui Y, Yamazaki N, Ogawa C, Kawai A, Narita Y, Esaki M, Yamamoto N: Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer Sci 113:4300-4310, 2022
        • Koyama T, Shimizu T, Sato J, Katsuya Y, Iwasa S, Kondo S, Yoshida T, Sudo K, Nishino M, Takiguchi Y, Yonemori K, Yamamoto N: Practical consideration for successful sequential tumor biopsies in first-in-human trials. Invest New Drugs 40:841-849, 2022
        • Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N: Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clin Cancer Res 28:1783-1791, 2022
        • Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS: Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res 28:95-105, 2022
        • Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T: Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. JAMA Netw Open 5:e2245081, 2022
        • Rumi Nishimura, Hiroto Ishiki, Jun Sato, Eriko Satomi, Dexamethasone for cancer-related dyspnoea.The Lancet. Oncology, 2022, 23(12):e525.
        • Shinobu Uzu, Jun Sato, Rika Wakao, Takahiro Nonaka, Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan. BMC health services research, 2022. 22(1):1292-1292.
        • Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto, Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research, 2022. 8(9):1783-1791.
        • Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front Oncol. 2022 Aug 26;12:925938.
        • Koyama T, Shimizu T, Sato J, Katsuya Y, Iwasa S, Kondo S, Yoshida T, Sudo K, Nishino M, Takiguchi Y, Yonemori K, Yamamoto N. Practical consideration for successful sequential tumor biopsies in first-in-human trials. Invest New Drugs. 2022 Aug;40(4):841-849.

          • 2021年

          • Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Shigehisa Kitano, Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Kazuki Sudo, Jun Sato, Kenji Tamura, Junichi Tomomatsu, Makiko Ono, Naoki Fukuda, Shunji Takahashi, A first-in-human. phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. Investigational new drugs. 2021:39(4):1036-1046..
          • Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto, First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate. in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clinical cancer research. 2021 27(14):3905-3915..
          • Kan Yonemori, Toshio Shimizu, Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Shigehisa Kitano, Jun Sato, Akihiko Shimomura, Ryota Shibaki, Ajit Suri, Yoichi Kase, Shuuji Sumino, Kenji Tamura, Noboru Yamamoto, The safety. tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese journal of clinical oncology. 2021 51(5):693-699..
          • Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto. First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer science. 2021 112(4):1514-1523..
          • Ken Masuda, Hidehito Horinouchi, Midori Tanaka, Ryoko Higashiyama, Yuki Shinno, Jun Sato, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of cancer research and clinical oncology. 2021 147(1):245-251..
          • Yazaki S, Yoshida T, Kojima Y, Yagishita S, Nakahama H, Okinaka K, Matsushita H, Shiotsuka M, Kobayashi O, Iwata S, Narita Y, Ohba A, Takahashi M, Iwasa S, Kobayashi K, Ohe Y, Yoshida T, Hamada A, Doi T, Yamamoto N: Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan. JAMA Oncol 7:1141-1148, 2021
          • Takahashi S, Fujiwara Y, Nakano K, Shimizu T, Tomomatsu J, Koyama T, Ogura M, Tachibana M, Kakurai Y, Yamashita T, Sakajiri S, Yamamoto N: Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Sci 112:2361-2370, 2021
          • Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S, Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N: Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Sci 112:3911-3917, 2021
          • Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C: Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. N Engl J Med 384:42-50, 2021
          • Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto, First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.Clinical cancer research, 2021.27(14):3905-3915.
          • Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, et al. A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer. 2021;24(4):835-43.
          • Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, Nakajima R, Miura T, Yamamoto N: First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clin Cancer Res 27:3905-3915, 2021

            • 2020年

            • Jun Sato, Shigehisa Kitano, Noriko Motoi, Yoshinori Ino, Noboru Yamamoto, Shunichi Watanabe, Yuichiro Ohe, Nobuyoshi Hiraoka. CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma. Cancer science. 2020:111(6):1921-1932..
            • Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto, Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre. phase 2 trial. The Lancet. Oncology. 2020 21(6):843-850..
            • Takaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, Jun Sato, Ryo Morita, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. Thoracic cancer. 2020 11(4):1038-1044..
            • Hanae Ida, Yasushi Goto, Jun Sato, Shintaro Kanda, Yuki Shinno, Ryou Morita, Shuji Murakami, Yuji Matsumoto, Tatsuya Yoshida, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Takahiro Fukuda, Ken Ohashi, Yuichiro Ohe, Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. Medical oncology (Northwood, London. England). 2020 37(4):30-30..
            • Jun Sato, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Natsuko Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Narikazu Boku. Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer. Inernational Journal of clinical oncology. 2020 11:526-537..
            • Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T: A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs 38:445-456, 2020
            • Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N: Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21:843-850, 2020
            • Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y: Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242-249, 2020
            • Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto, Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.The Lancet. Oncology, 2020.21(6):843-850.
            • Jun Sato, Shigehisa Kitano, Noriko Motoi, Yoshinori Ino, Noboru Yamamoto, Shunichi Watanabe, Yuichiro Ohe, Nobuyoshi Hiraoka, CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma. Cancer science, 2020. 111(6):1921-1932.
            • Sudo K, Kato K, Matsuzaki J, Takizawa S, Aoki Y, Shoji H, et al. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. Japanese Journal of Clinical Oncology. 2020;50(2):114-21.
            • Jun Sato, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Natsuko Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Narikazu Boku, Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer. Inernational Journal of clinical oncology. , 2020. 11: p. 526-537.
            • Katsuya Y, Miyake K, Higuchi T, Oshiro H, Sugisawa N, Singh SR, Goto Y, Zhao M, Hoffman RM. Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice. In Vivo. 2020 May-Jun;34(3):1027-1030.
            • Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N: First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci 111:571-579, 2020

              • 2019年

              • Tomoyuki Naito, Hibiki Udagawa, Jun Sato, Hidehito Horinouchi, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yoshitaka Zenke, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Yuichiro Ohe, Genichiro Ishii, Koichi Goto. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. Journal of thoracic oncology. 2019 14(10):1818-1827..
              • Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe. Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis. Journal of thoracic disease. 2019 11(7):2965-2972..
              • Jun Sato, Tatsunori Shimoi, Akihiko Shimomura, Emi Noguchi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Masayuki Yoshida, Kenji Tamura, The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. Internal medicine (Tokyo. Japan). 2019 58(10):1423-1428.. :738-743..
              • Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe. Mixed response to osimertinib and the beneficial effects of additional local therapy. Thoracic cancer. 2019 10(4)
              • Jun Sato, Akihiko Shimomura, Junpei Kawauchi, Juntaro Matsuzaki, Yusuke Yamamoto, Satoko Takizawa, Hiromi Sakamoto, Makoto Ohno, Yoshitaka Narita, Takahiro Ochiya, Kenji Tamura. Brain metastasis-related microRNAs in patients with advanced breast cancer. PloS one. 2019 14(10):e0221538..
              • Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, et al. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA network open. 2019;2(5):e194573-e.
              • Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, et al. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 2019.
              • Jun Sato, Akihiko Shimomura, Junpei Kawauchi, Juntaro Matsuzaki, Yusuke Yamamoto, Satoko Takizawa, Hiromi Sakamoto, Makoto Ohno, Yoshitaka Narita, Takahiro Ochiya, Kenji Tamura, Brain metastasis-related microRNAs in patients with advanced breast cancer. PloS one, 2019. 14(10):e0221538.
              • Jun Sato, Tatsunori Shimoi, Akihiko Shimomura, Emi Noguchi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Masayuki Yoshida, Kenji Tamura, The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. Internal medicine (Tokyo, Japan), 2019. 58(10):1423-1428.
              • Sawai Y, Katsuya Y, Shinozaki-Ushiku A, Iwasaki A, Fukayama M, Watanabe K, Nagase T. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab. Drug Discov Ther. 2019 Jul 22;13(3):164-167.
              • Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019 Jul;24(7):731-770.
              • Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, Nakamura K, Kuchiba A, Ohe Y. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019 May;113:78-86.
              • Koyama T, Kondo S, Shimizu T, Fujiwara Y, Morizane C, Sakamoto Y, Okusaka T, Yamamoto N: Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials. Front Oncol 9:301, 2019

                • 2018年以前

                • Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe. Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited. Journal of thoracic disease. 2018 10(3):1696-1702..
                • Yuki Shinno, Yasushi Goto, Sho Watanabe, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe. Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO open. 2018 3(7):e000399..
                • Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited. Journal of thoracic disease, 2018.10(3):1696-1702.
                • Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. Journal of Clinical Oncology. 2014;32(30):3400.
                • Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer research. 2014;74(15):4170-82.
                • Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, et al. ALDH‐1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular oncology. 2014;8(1):142-9.
                • Sudo K, Taketa T, Correa AM, Campagna M-C, Wadhwa R, Blum MA, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. Journal of clinical oncology. 2013;31(34):4306.
                • Cheedella N, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T,,,Sudo K, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Annals of Oncology. 2012;24(5):1262-6.